Prevalence of Hyperglycemia and Its Association with Breast Cancer Stage: A Case-Control Study in Meru County, Kenya
DOI:
https://doi.org/10.70619/vol6iss7pp25-38916Keywords:
HbA1c; hyperglycemia; breast cancer; Warburg effect; breast cancer staging; Kenya; Sub-Saharan Africa; case-control; BiomarkerAbstract
Background: Hyperglycemia, a hallmark of type 2 diabetes mellitus (T2DM), is increasingly implicated in breast cancer pathogenesis through the Warburg effect, hyperinsulinemia, and chronic inflammation. Understanding its prevalence and relationship with breast cancer stage in Sub-Saharan African populations remains critical for informing context-specific screening strategies.
Objectives: (1) To determine the prevalence of hyperglycemia (HbA1c ≥6.5%) among breast cancer patients compared to controls; and (2) to identify glycated hemoglobin (HbA1c) as a biomarker associated with different breast cancer stages.
Methods: A hospital-based case-control study enrolled 285 women (142 histologically confirmed breast cancer cases, 143 controls with non-cancerous breast masses) at Meru Teaching and Referral Hospital, Kenya. HbA1c was measured using a validated immunoturbidimetric analyser. Chi-square tests, independent samples t-tests, one-way ANOVA with Tukey’s HSD post-hoc analysis, and ROC curve analysis were applied.
Results: Hyperglycemia was documented in 84.5% of cases versus 34.3% of controls (p < 0.001). Mean HbA1c was 6.89±0.75% in cases versus 5.82±0.71% in controls (t(283) = 12.445, p < 0.001). ROC analysis identified HbA1c ≥6.5% as the optimal threshold (AUC = 0.751, sensitivity 84.5%, specificity 65.7%). Stage IV cases had the highest HbA1c (7.56±0.87%), with a significant post hoc difference between Stage II and Stage IV (mean difference = 0.782%, p = 0.031), although the overall ANOVA was borderline (F(3,139) = 2.599, p = 0.055).
Conclusion: HbA1c ≥6.5% is a prevalent and clinically meaningful biomarker in this Kenyan breast cancer population, with elevated values clustering at advanced disease stages. Integration of HbA1c into routine breast cancer screening and staging protocols is warranted.
References
Adedokun, B., Ademola, A., Makumbi, T., Odedina, S., Agwai, I., Ndom, P., Gakwaya, A., Ogundiran, T., Ojengbede, O., Huo, D., & Olopade, O. I. (2023). Unawareness of breast cancer family history among African women. Pan African Medical Journal, 45, Article 188. https://doi.org/10.11604/pamj.2023.45.188.21616
Antabe, R., Kansanga, M., Sano, Y., Kyeremeh, E., & Galaa, Y. (2020). Utilization of breast cancer screening in Kenya: What are the determinants? BMC Health Services Research, 20, Article 228. https://doi.org/10.1186/s12913-020-5073-2
Asiri, A., Al Qarni, A., Bakillah, A., & Arabia, S. (2024). The interlinking metabolic association between type 2 diabetes mellitus and cancer: Molecular mechanisms and therapeutic insights. Diagnostics, 14(19), Article 2132. https://doi.org/10.3390/diagnostics14192132
Ayoub, N. M., Jaradat, S. K., Alhusban, A., & Tahaineh, L. (2020). Glycosylated hemoglobin A1c is associated with anthropometric measurements and tumor characteristics in breast cancer patients. International Journal of Women's Health, 12, 139–149. https://doi.org/10.2147/ijwh.s234408
Bjornsdottir, H. H., Rawshani, A., Rawshani, A., Franzen, S., Svensson, A. M., Sattar, N., & Gudbjornsdottir, S. (2020). A national observation study of cancer incidence and mortality risks in type 2 diabetes compared to the background population over time. Scientific Reports, 10, Article 17376. https://doi.org/10.1038/s41598-020-74366-3
Brownlee, M. (2005). The pathobiology of diabetic complications: A unifying mechanism. Diabetes, 54(6), 1615–1625. https://doi.org/10.2337/diabetes.54.6.1615
Campbell, P. T., Newton, C. C., Jacobs, E. J., McCullough, M. L., Wang, Y., Rees-Punia, E., Guinter, M. A., Murphy, N., Koshiol, J., & Gapstur, S. M. (2022). Prospective associations of hemoglobin A1c and C-peptide with risk of diabetes-related cancers in the Cancer Prevention Study-II Nutrition Cohort. Cancer Research Communications, 2(7), 653–662. https://doi.org/10.1158/2767-9764.crc-22-0082
Cosmin Stan, M., & Paul, D. (2024). Diabetes and cancer: A twisted bond. Oncology Reviews, 18, Article 1354549. https://doi.org/10.3389/or.2024.1354549
DeBerardinis, R. J., & Chandel, N. S. (2020). We need to talk about the Warburg effect. Nature Metabolism, 2(2), 127–129. https://doi.org/10.1038/s42255-020-0172-2
Durrani, I. A., Bhatti, A., & John, P. (2021). The prognostic outcome of "type 2 diabetes mellitus and breast cancer" association pivots on hypoxia-hyperglycemia axis. Cancer Cell International, 21, Article 172. https://doi.org/10.1186/s12935-021-02040-5
Fitzpatrick, D., Pirie, K., Reeves, G., Green, J., & Beral, V. (2023). Combined and progestagen-only hormonal contraceptives and breast cancer risk: A UK nested case-control study and meta-analysis. PLOS Medicine, 20(3), Article e1004188. https://doi.org/10.1371/journal.pmed.1004188
Fleiss, J. L., Levin, B., & Paik, M. C. (2003). Statistical methods for rates and proportions (3rd ed.). Wiley.
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010). Diabetes and cancer: A consensus report. Diabetes Care, 33(7), 1674–1685. https://doi.org/10.2337/dc10-0666
Glassman, I., Le, N., Asif, A., Goulding, A., Alcantara, C. A., Vu, A., Chorbajian, A., Mirhosseini, M., Singh, M., & Venketaraman, V. (2023). The role of obesity in breast cancer pathogenesis. Cells, 12(16), Article 2061. https://doi.org/10.3390/cells12162061
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013
Hu, J., Geng, T., Li, L., Pan, A., & Liu, G. (2021). Association of time since diabetes diagnosis with cardiovascular and cancer outcomes. JAMA Network Open, 4(12), Article e2138560. https://doi.org/10.1001/jamanetworkopen.2021.38560
Hutchinson, B., Watts, R., Nyangasi, M., Anderson, B., Chepchumba, J., Wangia, E., Jalang', R., Mwenda, V., Yerramilli, P., Kuguru, T., Kabubei, K., Gordillo-Tobar, A., Meheus, F., Meyer, C., Ilbawi, A., & Nugent, R. (2024). An economic evaluation of breast cancer interventions in Kenya. eClinicalMedicine, 77, Article 102894. https://doi.org/10.1016/j.eclinm.2024.102894
Joshu, C. E., Prizment, A. E., Dluzniewski, P. J., Menke, A., Folsom, A. R., Coresh, J., Yeh, H.-C., Brancati, F. L., Platz, E. A., & Selvin, E. (2012). Glycated hemoglobin and cancer incidence and mortality in the Atherosclerosis in Communities (ARIC) Study, 1990–2006. International Journal of Cancer, 131(7), 1667–1677. https://doi.org/10.1002/ijc.27394
Jousheghany, F., Phelps, J., Crook, T., & Hakkak, R. (2016). Relationship between level of HbA1c and breast cancer. BBA Clinical, 6, 45–48. https://doi.org/10.1016/j.bbacli.2016.04.005
Lam, B. Q., Srivastava, R., Morvant, J., Shankar, S., & Srivastava, R. K. (2021). Association of diabetes mellitus and alcohol abuse with cancer: Molecular mechanisms and clinical significance. Cells, 10(11), Article 3077. https://doi.org/10.3390/cells10113077
Li, W., Ma, X., Li, N., Liu, H., Dong, Q., Zhang, J., Yang, C., Liu, Y., Liang, Q., Zhang, S., Lu, X., & Chen, Y. (2016). Resveratrol inhibits hexokinases II-mediated glycolysis in non-small cell lung cancer via targeting Akt signaling pathway. Experimental Cell Research, 349(2), 320–327.
Liang, X.-Y., Mu, L., Hu, L., She, R., Ma, C., Feng, J., Jiang, Z., Li, Z., Qu, X., Peng, B., Wu, K., & Kong, L. (2024). Optimal glycated hemoglobin cutoff for diagnosis of diabetes and prediabetes in Chinese breast cancer women. International Journal of General Medicine, 17, 1807–1822. https://doi.org/10.2147/ijgm.s457158
Liu, X., Zheng, W., Fan, C., Lin, W., & Shi, L. (2018). Increased GLUT1 correlates with clinicopathological characteristics and poor survival in pancreatic cancer. International Journal of Clinical and Experimental Medicine, 11, 5568–5576.
Ngwa, W., Addai, B. W., Adewole, I., Ainsworth, V., Alaro, J., Alatise, O. I., Ali, Z., Anderson, B. O., Anorlu, R., Avery, S., & et al. (2022). Cancer in sub-Saharan Africa: A Lancet Oncology Commission. The Lancet Oncology, 23(6), e251–e312. https://doi.org/10.1016/s1470-2045(21)00720-8
Pavlova, N. N., & Thompson, C. B. (2016). The emerging hallmarks of cancer metabolism. Cell Metabolism, 23(1), 27–47. https://doi.org/10.1016/j.cmet.2015.12.006
Riogi, B., Ross, C., Mutebi, M., & Dave, R. V. (2022). The Kenya UK Breast Cancer Awareness Week: Curriculum codesign and codelivery with direct and lived experience of breast cancer diagnosis and management. BMJ Global Health, 7(5), Article e008755. https://doi.org/10.1136/bmjgh-2022-008755
Rioki, J. N., Muchiri, L., Mweu, M., Nyagol, J., Songok, E., Mwangi, J., Oyaro, M., Bwire, L., & Rogena, E. (2023). BRCA1 and BRCA2 mutations and their clinical relevance in selected women diagnosed with triple-negative breast cancer in Kenya. Pan African Medical Journal, 45, Article 102. https://doi.org/10.11604/pamj.2023.45.102.36431
Sayed, S., Moloo, Z., Wasike, R., Bird, P., Oigara, R., Njoroge, F. W., Shaikh, A. J., Prasad, S. V., Vinayak, S., Gierach, G. L., Dawsey, S. M., Palakal, M., Fan, S., Mullooly, M., Chauhan, R., Okiro, P., Gakinya, S., Nzioka, A., Kyobutungi, C., & Mohamed, S. (2017). Ethnicity and breast cancer characteristics in Kenya. Breast Cancer Research and Treatment, 167(2), 425–437. https://doi.org/10.1007/s10549-017-4511-2
Sayed, S., Fan, S., Moloo, Z., Wasike, R., Bird, P., Saleh, M., Shaikh, A. J., Figueroa, J. D., Naidoo, R., Makokha, F. W., Gardner, K., Oigara, R., Njoroge, F. W., Magangane, P., Mutebi, M., Chauhan, R., Mwanzi, S., Govender, D., & Yang, X. R. (2021). Breast cancer risk factors in relation to molecular subtypes in breast cancer patients from Kenya. Breast Cancer Research, 23, Article 19. https://doi.org/10.1186/s13058-021-01446-3
Shikata, K., Ninomiya, T., & Kiyohara, Y. (2013). Diabetes mellitus and cancer risk: Review of the epidemiological evidence. Cancer Science, 104(1), 9–14. https://doi.org/10.1111/cas.12043
Stattin, P., Bjor, O., Ferrari, P., Lukanova, A., Lenner, P., Lindahl, B., Hallmans, G., & Kaaks, R. (2007). Prospective study of hyperglycemia and cancer risk. Diabetes Care, 30(3), 561–567. https://doi.org/10.2337/dc06-0922
Twahir, M., Oyesegun, R., Yarney, J., Gachii, A., Nwogu, C., Mangutha, G., Anderson, P., & Benjamin, E. (2021). Real-world challenges for patients with breast cancer in sub-Saharan Africa. BMJ Open, 11(5), Article e041900. https://doi.org/10.1136/bmjopen-2020-041900
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009). Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science, 324(5930), 1029–1033. https://doi.org/10.1126/science.1160809
Wassie, M., Zegeye, A. F., Aemro, A., Terefe, B., Zeleke, G. A., Workneh, B. S., Tekeba, B., Ali, M. S., Mekonen, E. G., & Tamir, T. T. (2024). Awareness and its determinant factors towards breast examination to detect breast cancer among reproductive age women in Kenya. PLOS ONE, 19(12), Article e0314700. https://doi.org/10.1371/journal.pone.0314700
Zhang, F., de Bock, G. H., Landman, G. W., Zhang, Q., van der Vegt, B., & Sidorenkov, G. (2025). Longitudinal changes in metabolism-related metrics and breast cancer risk: A general population study. Breast Cancer Research, 27, Article 33. https://doi.org/10.1186/s13058-025-02105-7
Zhang, J., Lu, Y., Zhang, N., Yu, Z., Li, H., He, R., Mao, Y., & Zhu, B. (2023). Global burden of female breast cancer and its association with socioeconomic development status, 1990–2044. Cancer Reports, 6(S1), Article e1827. https://doi.org/10.1002/cnr2.1827
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Herbert W. Kibebe, Eric M. Muchiri, Maryjoy Kaimuri
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
